Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials

被引:14
作者
Murugiah, Karthik [1 ,2 ]
Ritchie, Jessica D. [1 ]
Desai, Nihar R. [1 ,2 ]
Ross, Joseph S. [1 ,3 ,4 ]
Krumholz, Harlan M. [1 ,2 ,3 ,4 ]
机构
[1] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA
[2] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA
[3] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06510 USA
[4] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2016年 / 5卷 / 04期
关键词
data sharing; trials; OPEN SCIENCE; RISK;
D O I
10.1161/JAHA.116.003307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Industry-sponsored clinical trials produce high-quality data sets that can be used by researchers to generate new knowledge. We assessed the availability of individual participant-level data (IPD) from large cardiovascular trials conducted by major pharmaceutical companies and compiled a list of available trials. Methods and Results-We identified all randomized cardiovascular interventional trials registered on ClinicalTrials.gov with >5000 enrollment, sponsored by 1 of the top 20 pharmaceutical companies by 2014 global sales. Availability of IPD for each trial was ascertained by searching each company's website/data-sharing portal. If availability could not be determined, each company was contacted electronically. Of 60 included trials, IPD are available for 15 trials (25%) consisting of 204 452 patients. IPD are unavailable for 15 trials (25%). Reasons for unavailability were: cosponsor did not agree to make IPD available (4 trials) and trials were not conducted within a specific time (5 trials); for the remaining 6 trials, no specific reason was provided. For 30 trials (50%), availability of IPD could not be definitively determined either because of no response or requirements for a full proposal (23 trials). Conclusions-IPD from 1 in 4 large cardiovascular trials conducted by major pharmaceutical companies are confirmed available to researchers for secondary research, a valuable opportunity to enhance science. However, IPD from 1 in 4 trials are not available, and data availability could not be definitively determined for half of our sample. For several of these trials, companies require a full proposal to determine availability, making use of the IPD by researchers less certain.
引用
收藏
页数:8
相关论文
共 15 条
  • [1] [Anonymous], 2014, LILLY ANNOUNCES INCR
  • [2] [Anonymous], 2014, BAYER NEWS
  • [3] ClinicalStudyDataRequest, 2013, CLINICALSTUDYDATAREQ
  • [4] Institute of Medicine, 2015, SHAR CLIN TRIAL DAT
  • [5] Open Access to Clinical Trials Data
    Krumholz, Harlan M.
    Peterson, Eric D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (10): : 1002 - 1003
  • [6] Sea Change in Open Science and Data Sharing Leadership by Industry
    Krumholz, Harlan M.
    Gross, Cary P.
    Blount, Katrina L.
    Ritchie, Jessica D.
    Hodshon, Beth
    Lehman, Richard
    Ross, Joseph S.
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (04): : 499 - 504
  • [7] Statin Therapy and Risk of Fracture Results From the JUPITER Randomized Clinical Trial
    Pena, Jessica M.
    Aspberg, Sara
    MacFadyen, Jean
    Glynn, Robert J.
    Solomon, Daniel H.
    Ridker, Paul M.
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (02) : 171 - 177
  • [8] Pharmaceutical Research and Manufacturers of America (PhRMA), 2015, PRINC RESP CLIN TRIA
  • [9] PhRMA and EFPIA, 2013, PRINC RESP CLIN TRIA
  • [10] PMLive, 2015, FINANCIAL TIMES 0121